Phenotypic resistance to activated protein C (APC) is a complex mechanism associated with increased thrombosis risk. Activated protein C resistance (APCR) is mainly influenced by FV Leiden mutation, and various other single nucleotide polymorphisms (SNPs) in FV gene are known to be associated with APCR. The aim of present study was to investigate the incidence and assess possible mechanisms of APCR in Indian patients with deep vein thrombosis (DVT). Three hundred and ten Doppler-proven patients with DVT were screened for APCR, and 50 APCR positive patients and 50 controls were typed for FV Leiden , Hong Kong, Cambridge, HR2 haplotype, Glu666Asp, Ala485Lys, and Liverpool using either polymerase chain reaction (PCR)-restriction fragment length polymorphism or allele specific PCR. FV Leiden was commonest cause of APCR (50%) in Indian patients with DVT being statistically significant (P ¼ .001) compared to controls. FV Liverpool, FV Glu666Asp and FV Ala485Lys were studied for the first time in Indian population. FV Liverpool, FV Glu666Asp, Hong Kong, and Cambridge were found to be absent. High frequency of Ala485Lys in patients shows that it might be a risk factor contributing to APCR in Indian patients with DVT. HR2 haplotype was not associated with APCR; however, presence of homozygous HR2 haplotype in patients only indicates the role it might play in Indian APCR population. In conclusion, contribution of FV Leiden causing APCR in Indian population is not as strong as previously reported in Western countries. The presence of other SNPs observed in the present study requires such studies on larger sample size to understand the molecular basis of defect.
Introduction
Proteolytic inactivation of FVa and FVIIIa by activated protein C (APC) is a crucial mechanism involved in downregulation of the coagulation pathway. Activated protein C mediates cleavage of intact FV at positions arginine (Arg) 306, Arg506, and Arg679; which then inactivates FVIIIa, thus causing downregulation of the procoagulant activity of FV. 1 Functional abnormalities of this pathway manifesting in the form of phenotypic resistance to APC are associated with an increased risk of venous thromboembolism. 2 Activated protein C resistance (APCR) first observed in 1993 3 occurs with a frequency of 20% to 60% in patients with venous thromboembolism. 4 Activated protein C resistance is mainly caused by mutations in the FV gene. FV was first discovered in 1947 5 and is an important enzyme required for maintaining normal hemostatic balance as it plays a dual role of being a procoagulant and an anticoagulant. The gene for FV is 80 kb in length and is located on chromosome 1q23. 6 Various single nucleotide polymorphisms (SNPs) in the FV gene have been reported to be associated with APCR. FV Leiden is the commonest cause of DVT with its frequency being 60% in patients with DVT and 2% to 15% in general population. 7 Genetic basis of FV Leiden was first described in 1994 when G to A substitution at position 1691 was shown to result in substitution of glutamine (Gln) in place of Arg at position 506, which is the prime target site for APC-mediated inactivation of FVa. 8 In addition to FV Leiden , the FV Hong-Kong and Cambridge are 2 mutations present at Arg306 APC cleavage site associated with reduced APC cofactor activity in FVIII inactivation and mild APCR. 9,10 R2 allele or HR2 haplotype either independently or in association with FV Leiden mutation has also been reported to be associated with APCR. However, its role in causing APCR and thus increased risk of thrombosis is controversial. [11] [12] [13] Another FV-related causes of APCR were associated with FV Liverpool, FV Glu666Asp, and FV Ala485Lys mutations and have not been previously studied in Indian population. [14] [15] [16] An earlier study from our group reported only 50% of APCR positive patients to be carrying FV Leiden mutation in patients with DVT. 17 However, there was a major point of difference in the root cause of APCR in Indian population from the Caucasian population. This discrepancy increased the possibility that the Indian population having thrombosis with APCR may be carrying mutations other than FV Leiden contributing toward APCR. The present study was undertaken to investigate the incidence and assess possible role of other FV SNPs with APCR in Indian patients with DVT.
Materials and Methods

Patient/Control Population
We screened 310 Doppler-proven patients with DVT in the time span of about 2 years (October 2011-August 2013) for APCR. Only patients with APCR positive (50 of 310) were included in the present study. The mean age of the patients was 41.1 + 5.5 (range 23-54) years. Patients receiving thrombotic drugs or oral anticoagulants were excluded from the study, as were patients with malignancy, pregnancy, liver disease, acute thrombotic phase, and oral contraceptive users as these factors can affect APCR testing.
Fifty healthy controls of similar age-group (40.1 + 5.2, range 23-52) were recruited from the same geographical area. The controls had no history of arterial and venous thrombotic diseases. All the patients as well as controls gave written consent to enter the study, and ethical clearance was obtained from Institute Ethics Committee of All India Institute of Medical Sciences, New Delhi, India.
Sample Collection and Plasma Separation
Blood samples (10 mL) were collected in siliconized glass containers, containing 3.2% trisodium citrate solution. Plasma was separated by centrifugation for 10 minutes at 2000g at room temperature and stored at À70 C till further use. Sample collection was delayed until at least 3 to 6 months following the acute thrombotic event to rule out the possibility of falsepositive results.
Laboratory Testing
Activated protein C resistance was assessed by measuring the anticoagulant response in plasma on the addition of APC (Coatest; Chromogenix, Sweden). A ratio of <2.1 for the clotting time in the presence of APC/clotting time in the absence of APC was taken to represent APCR. All the APCR positive patients and controls were tested for FV Leiden and other common FV mutations/polymorphisms, known to contribute to APCR. RNA-free genomic DNA was isolated from peripheral blood leukocytes using the Bioserve DNA isolation kit. DNA concentration was determined using NanoDrop device. Mutational analysis for FV Leiden , Hong Kong, Cambridge, and HR2 haplotype was done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and screening protocols are shown in Table 1 . FV Liverpool, FV Glu666Asp, and FV Ala485Lys polymorphisms were identified using allele-specific PCR ( Table 2 ). 
Statistical Analysis
Results
Of the 310 patients, 50 (50 of 310 ¼ 16.1%) were found to be APCR positive. None of the 50 controls were positive for APCR. Table 3 shows the comparison of the various congenital causes of APCR with respect to healthy controls. FV Leiden accounted for 50% (25 of 50) of all APCR positive patients in the present study, and the difference in the group frequencies compared with controls was found to be statistically significant (P ¼ .001). FV HR2 haplotype was seen in 16% (8 of 50) of patients and 10% (5 of 50) of controls but this difference was not statistically significant (P ¼ .554). Four patients showed coexistence of FV Leiden mutation with HR2 haplotype. FV Ala485Lys polymorphism was seen in 26% (13 of 50) of patients and 14% (7 of 50) of controls, and this difference was not associated with APCR (P ¼ .134). Ten percentage (5 of 50) of patients were double heterozygotes for FV Leiden and FV Ala485Lys polymorphisms. None of the patients and controls carried the FV Hong-Kong, Cambridge, Liverpool, and Glu666Asp mutations.
Discussion
Activated protein C resistance, a poor anticoagulant response of APC in hemostasis, is the most common cause of DVT. A large number of studies from the caucasian as well as Asian population have stressed on the association of APCR with DVT. However, the strength of association between DVT and various risk factors contributing to APCR still remains to be elucidated. The prevalence of APCR varies from population to population. The frequency of APCR among patients with venous thrombosis, depending on the selection criteria, ranges from 20% to 60%. Our present study showed a prevalence rate of 16.1% (50 of 310), which is somewhat lower than 20% (31 of 155) of prevalence rates obtained by our previous group 17 and higher than 12.5% obtained by Bhattacharyya et al in north Indian population. 18 Inherited APCR because of the FV Leiden mutation has been shown to be clearly associated with APCR in population with thrombosis. 3, 8, 19 Present study showed APCR at a higher frequency than FV Leiden mutation. We identified only 50% of APCR positive patients carrying FV Leiden mutation. Our group had earlier reported similar findings, 17 although the proportion of patients showing APCR and carrying FV Leiden mutation was slightly higher (51.6%) in that study. This percentage is much lower than that for caucasians which is estimated at 95%. 3, 8, 20 This discrepancy increased the possibility that the Indian population having thrombosis with APCR may be carrying mutations other than FV Leiden contributing toward APCR. Various mutations in the FV gene excluding FV Leiden , particularly at the other cleavage sites of FV gene, Arg306 and Arg679, have the potential to contribute to the APCR. FV Hong-Kong and Cambridge are 2 mutations present at Arg306 APC cleavage site associated with reduced APC cofactor activity in FVIII inactivation and mild APCR. Genotyping for the Hong Kong/Cambridge mutations in our study did not reveal a single mutant type (homozygote or heterozygote) of these mutations in either patients or controls. This can be expected as these mutations have shown to be of very rare occurrence similar to other Asian population. 9,10,21 FV HR2 haplotype showed a prevalence rate of 8 (16%) and 5 (10%) in the patient and control population, respectively, which was not significantly different (P ¼ .554). Genotyping for the FV HR2 haplotype showed a prevalence rate of 12% and 10% for the R1R2 heterozygous genotype in the patients and control population respectively, which was not significantly different (P value ¼ .749). However, the presence of 2 patients with the FV HR2 homozygous condition and absence in control population indicate that FV HR2 in its homozygous mutant (R2R2) form may be contributory toward APCR. A large sample size is required to find out the correct association of HR2 haplotype with APCR.
Another FV-related cause for APCR is associated with FV Liverpool (Ile359Thr) and FV Glu666Asp mutations. As per our best knowledge, the present study has studied these mutations in Indian population with thrombosis for the first time. Genotyping for the FV Liverpool and FV Glu666Asp mutations in our study population showed that both mutations were absent in all the patients and controls. Recently, Xing-Guang et al described low prevalence of FV Glu666Asp mutations in Chinese patients with DVT as well as they did not found significant association of Glu666Asp mutation with APCR. 15 It can be assumed that these mutations may be very rare in Asian Indian population. FV Ala485Lys polymorphism in our study was not associated with APCR in patients with DVT when compared with controls (P ¼ .134). Our result is corresponding with a previous study where no association between FV Ala485Lys polymorphism and APCR in patients with DVT was observed in a Thai population with DVT. 22 However, Le et al reported that individuals who were homozygous or heterozygous for the Ala485Lys polymorphism had significantly lower normalized APC ratios than those with the normal genotype in the patients with coronary artery disease. 16 In our study, no patients and control were homozygous for the polymorphism that might reflect our finding. Ala485Lys polymorphism occurs in a highly conserved a-loop in the A2 domain, and its location is close to position Arg506. We can guess that the Lys residue may affect loop structure and cleavage site of Arg506 of APC inactivation. Unfortunately, no study explains the molecular mechanism of APCR in carriers of the Ala485Lys polymorphism. In the present study, only FV Leiden was observed to be associated with APCR, whereas rests of the FV polymorphisms/mutations were not significantly associated with APCR. It is quite possible that acquired factors like presence of FVIII, LAC, and b2 glycoproteins might contribute to APCR in FV Leiden -negative patients with thrombosis.
In conclusion, FV Leiden is the major cause of inherited APCR in Indian patients with DVT. However, unlike in the West, FV Leiden mutation may not contribute to APCR as strongly in the Asian Indian population as it does in the Caucasian population. Other rare SNPs like Hong-Kong, Cambridge, FV Liverpool, and FV Glu666Asp are very rare in Indian population similar to other Asian studies. Presence of 2 patients with FV HR2 homozygous condition in APCR patients indicates that FV HR2 in its homozygous mutant form may be contributory toward the APCR. A high frequency of Ala485Lys in the present study shows that it might be a risk factor contributing to APCR in Indian patients with DVT. Future studies with a larger sample size are required to make a correct assessment posed by these FV SNPs.
